Expression of metastasis-associated protein 3 in human brain glioma related to tumor prognosis

被引：19

作者：

Shan S. ^{[1
]}

Hui G. ^{[1
]}

Hou F. ^{[2
]}

Shi H. ^{[1
]}

Zhou G. ^{[1
]}

Yan H. ^{[1
]}

Wang L. ^{[1
]}

Liu J. ^{[1
]}

机构：

[1] Qingdao First Sanatorium of Jinan Military Region, Qingdao, 266071, Shandong

[2] Qingdao Second Sanatorium of Jinan Military Region, Qingdao, 266071, Shandong

来源：

Neurological Sciences | 2015年 / 36卷 / 10期

关键词：

Glioma; Immunohistochemistry; MTA3; Prognosis;

D O I：

10.1007/s10072-015-2252-8

中图分类号：

学科分类号：

摘要：

Glioma represents a disparate group of tumors characterized by high invasion ability, and therefore it is of clinical significance to identify molecular markers and therapeutic targets for better clinical management. Previously, metastasis-associated protein family (MTA) is considered to promote tumor cell invasion and metastasis of human malignancies. Recently, the newly identified MTA3 has been shown to play conflicting roles in human malignancies, while the expression pattern and potential clinical significance of MTA3 in human glioma have not been addressed yet. In the present study, we investigated the protein expression of MTA3 by immunohistochemistry assay and analyzed its association with glioma prognosis in 186 cases of patients. Results showed that MTA3 expression was decreased in glioma compared with that in normal brain (P < 0.05). In addition, tumors with high MTA3 expression were more likely to be of low WHO grade (P = 0.005) and reserve of body function (P = 0.014). Survival analysis showed that decreased MTA3 expression was independently associated with unfavorable overall survival of patients (P < 0.001). These results provide the first evidence that MTA3 expression was decreased in human glioma and negatively associated with prognosis of patients, suggesting that MTA3 may play a tumor suppressor role in glioma. © 2015, Springer-Verlag Italia.

引用

页码：1799 / 1804

页数：5

共 30 条

[1]

Siegel R., Naishadham D., Jemal A., Cancer statistics, CA Cancer J Clin, 63, pp. 11-30, (2013)

[2]

Noll K.R., Sullaway C., Ziu M., Weinberg J.S., Wefel J.S., Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection, Neuro Oncol, 17, pp. 580-587, (2015)

[3]

Blaes J., Weiler M., Sahm F., Hentschel B., Osswald M., Czabanka M., Et al., NDRG1 prognosticates the natural course of disease in WHO grade II glioma, J Neuro Oncol, 117, pp. 25-32, (2014)

[4]

Mangla R., Ginat D.T., Kamalian S., Milano M.T., Korones D.N., Walter K.A., Et al., Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes, J Neuro Oncol, 116, pp. 325-331, (2014)

[5]

Rhun E.L., Taillibert S., Chamberlain M.C., The future of high-grade glioma: where we are and where are we going, Surg Neurol Int, 6, pp. S9-S44, (2015)

[6]

Wicks R.T., Azadi J., Mangraviti A., Zhang I., Hwang L., Joshi A., Et al., Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma, Neuro Oncol, 17, pp. 70-80, (2015)

[7]

Mistry M., Zhukova N., Merico D., Rakopoulos P., Krishnatry R., Shago M., BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma, J Clin Oncol Off J Am Soc Cl, (2015)

[8]

Erson-Omay E.Z., Caglayan A.O., Schultz N., Weinhold N., Omay S.B., Ozduman K., Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis, Neuro Oncol, (2015)

[9]

Liu J., Wang H., Huang C., Qian H., Subcellular localization of MTA proteins in normal and cancer cells, Cancer Metastasis Rev, (2014)

[10]

Jang K.S., Paik S.S., Chung H., Oh Y.H., Kong G., MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers, Cancer Sci, 97, pp. 374-379, (2006)

← 1 2 3 →